Solini et al. [92] investigated the association of diabetes mellitus type 2 (T2DM) or metabolic-syndrome-related kidney disease with P2X7R, and found that mice lacking P2X7R had reduced inflammation, fibrosis, and oxidative stress in the kidney with a downregulation of NLRP3 inflammasome activation, suggesting that P2X7R and NLRP3 could be used as therapeutic targets for DN. Here, NLRP3 is linked to kidney disorder.